Interestingly, a recent study in patient breast cancer samples and cell lines revealed that elevated expression of factors that promote chromatin accessibility and gene expression, such as COMPASS, BAF, KDM4B and KAT6B, lead to increased sensitivity to anthracycline treatment, whereas factors that promote chromatin compaction, such as PRC2, lead to anthracycline resistance (57). Here, KAT6B is linked to breast cancer.